key: cord-0847777-0btjz1lp authors: Rathod, Shrinivas; Dubey, Arbind; Bashir, Bashir; Sivananthan, Gokulan; Leylek, Ahmet; Chowdhury, Amitava; Koul, Rashmi title: Bracing for impact with new 4R’s in the COVID-19 pandemic- a provincial thoracic radiation oncology consensus date: 2020-04-08 journal: Radiother Oncol DOI: 10.1016/j.radonc.2020.03.045 sha: 3fcfc02d44d2f4184a63610894bf8bf509429afe doc_id: 847777 cord_uid: 0btjz1lp As COVID-19 pandemic continues to explode, cancer centers worldwide are trying to adapt and are struggling with this constantly changing scenario. Intending to ensure patient safety and deliver quality care, we sought consensus on the preferred thoracic radiation regimen in a Canadian province with 4 new R’s of COVID era. The world and health care system is scrambling as COVID-19 pandemic continues to explode. 1 As of 24th March 2020, over 400,000 cases are reported worldwide and the numbers keep rising constantly. 1 Apart from the Artic, it has engulfed every continent and country. With this unimaginable scenario, the healthcare system in the entire world is under immense pressure and struggling to cope. Available data shows COVID-19 carries high risk or morbidity and mortality for elderly and immuno-compromised individuals. 2 Reports from China show Cancer patients have an aggressive course and carry a 3.5 higher risk of mortality. 3 The study also found patients with cancer deteriorated more rapidly than those without cancer (median time to severe events 13 days vs 43 days). 3 Cancer centers worldwide are trying to adapt and are struggling with this constantly changing scenario. Hospitals are designing new policy measures and working hard to implement those in place. Radiation Oncology is an integral part of oncology care and the nature of fractionated treatment requires patients to visit cancer centers daily for a significant number of days. The risk of patient contacting/getting exposed to and diffusion of spread is paramount. 4 The risk of decrease in specialized radiation oncology workforce could hamper and even halt operations of radiation oncology centers. 5 Learning from Chinese and Italian experience, aiming to reduce the impact of epidemic operations changes several are recommended. 4, 6, 7 Radiation oncology community must evaluate options of prioritizing radiation treatments, deferring where applicable, omitting where there is no or very minimal benefit and strongly consider reduce numbers of fractions where there is evidence to support. 8 We proposed 4 new R's in the COVID era [1] ViRtual care (reduce in-person consult / follow up / on treatment visits) [2] Ration radiation (ofer radiation wisely and avoid RT where minimal benefit) [3] defeR radiation (as appropriate) [4] hypofRactionate radiation (where applicable) and came up with provincial preferred thoracic radiation regimen. Several measures are adopted by Canadian physicians such as virtual care to minimize inperson clinic visits and deferral where needed. Intending to ensure patient safety and deliver quality care, we sought consensus on the preferred thoracic hypofractionated radiation regimen in our provincial cancer center. CancerCare Manitoba provides comprehensive oncology services for the province of With provincial emergency declarations, Thoracic Radiation oncology (RO) group was tasked with disease specific COVID-19 emergency preparedness plan. Our Team reviewed the current evidence to assess the role and available options of different radiation regimens in the management of lung cancers. We assessed different common scenarios where radiation would be routinely considered and prioritized the indications. Priority levels were assigned based on prognosis and the expected benefit of radiation treatment. Curative treatments, where delay/deferral would jeopardize the survival outcomes, were considered as a high priority. Treatment indications for symptomatic measures or consolidation (treatment gains in quality of life or progression-free survival) were considered as an intermediate priority. Treatment indications where the role of radiation is debatable (no significant overall survival impact or other options as observation were appropriate) were considered as low priority. Thoracic RO team attained consensus and recommended evidence-based preferred hypofractionated radiation regimen for clinical care at our provincial comprehensive cancer center. Nonsmall cell Lung Cancers: Stage I-II NSCLC: Priority level -high: RO Consensus: Stage I-II (node negative) NSCLC represents a curative scenario and nonsurgical candidates with good performance status should undergo stereotactic body radiation treatment. Peripheral tumours should be treated with 54Gy in 3 fractions and preferred over 48 Gy in 4 Fr option. 9,10 We do not practice 30-34Gy in 1 fraction at our center yet, however once available could be preferred or appropriate patients. 10 Central tumours should be treated with 50Gy in 5 Fr was recommended as a preferred option. 11 Group discouraged the use of 60 Gy in 8 Fr for central tumours. However, this would be considered a valid option for the treatment of ultra-central tumours. The use of hypofractionated regimen as 60Gy in 15 Fr is not preferred unless the patient is not a candidate for SBRT. 12 Stage II (node positive) -III NSCLC: Priority level -high: RO Consensus: Group agreed inoperable stage II (node positive) -III population with good performance status would be best served with curative concurrent chemo radiation with standard doses of 60Gy in 30 Fr. 13 Our group did not support concurrent chemo and hypofractionated radiation options. We discouraged the use of a longer regimen such as 66 Gy in 33 Fr at present. 13 Summary details of priority and recommended radiation regimen are shown in figure 1 and table 1 respectively. With the current pandemic and the associated restrictions, we believe this preferred RT regimen will serve as a policy document for the thoracic radiation community (table 1 and figure 1). The model of viRtual care (reduce in-person consult / follow up / on treatment visits), Ration radiation (ofer radiation wisely and avoid RT where minimal benefit), defeR radiation (as appropriate), hypo fRactionate radiation (where applicable) are emerging as new 4R's of radiation therapy. .These measures will be helpful to minimize patient visits to radiation centers and reduce the risk of patient exposure to infection. The preferred hypo fractionated regimen may help minimize the impact of COVID19 on in these unprecedented and unfortunate times. We are hopeful these measures will help mitigate the impact of COVID-19 pandemic on our patients and cancer centers. In the current times, 4 new R's of Radiation treatment will help mitigate the impact of COVID-19 pandemic on our patients and cancer centers. Clinical Characteristics of Coronavirus Disease 2019 in China Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Covid-19 Outbreak in Northern Italy: First Practical Indications for Radiotherapy Departments he Impact of COVID-19 on Radiation Oncology Clinics and Cancer Patients in the U.S. Advances in Radiation Oncology Running a Radiation Oncology Department at the time of coronavirus: an Italian experience. Advances in Radiation Oncology Saeed: COVID-19: Global Radiation Oncology's Targeted Response for Pandemic Preparedness Radiotherapy in the time of the Coronavirus pandemic: when less is better Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer -Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial Long-Term Results of NRG Oncology RTOG 0617: Standard-Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer Quality of Life Outcomes in a Phase 3 Randomized Trial of Optimization of Treatment of Advanced Non-small Cell Lung Cancer Using Radiation Therapy and Chemotherapy: IAEA Multicentric Randomized Phase 3 Study (NCT00864331) Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an openlabel, phase 3, randomised, superiority trial Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data metaanalysis Role of Stereotactic Body Radiation Therapy in Early Stage Small Cell Lung Cancer in the Era of Lung Cancer Screening: A Systematic Review Trends in stereotactic body radiation therapy for stage I small cell lung cancer Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial Prophylactic cranial irradiation in extensive small-cell lung cancer Legends: Gy-Gray, Fr-fraction, SBRT-sterotactic body radiation treatment, RT -radiation, CTchemotherapy, NSCLC-non small cell lung cancer, SCLC-small cell lung cancer